EA201790766A1 - Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 - Google Patents

Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1

Info

Publication number
EA201790766A1
EA201790766A1 EA201790766A EA201790766A EA201790766A1 EA 201790766 A1 EA201790766 A1 EA 201790766A1 EA 201790766 A EA201790766 A EA 201790766A EA 201790766 A EA201790766 A EA 201790766A EA 201790766 A1 EA201790766 A1 EA 201790766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methilpiperidine
synthase
new
microsomal prostaglandin
connections suitable
Prior art date
Application number
EA201790766A
Other languages
English (en)
Other versions
EA032428B1 (ru
Inventor
Мэттью Джозеф Фишер
Стивен Ли Каклиш
Питер Рудольф Маннинен
Кэтрин Мари Партридж
Мэтью Аллен Шиффлер
Алан М. Варшавски
Джереми Шуленбург Йорк
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201790766A1 publication Critical patent/EA201790766A1/ru
Publication of EA032428B1 publication Critical patent/EA032428B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

В настоящем изобретении предложены соединения формулы 1или их фармацевтически приемлемая соль, отличающиеся тем, что R, R1 и G являются такими, как определено в описании изобретения; способы получения указанных соединений и применение указанных соединений для лечения боли и/или воспаления, связанных с артритом или остеоартритом.
EA201790766A 2014-10-29 2015-10-22 Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e-синтазы 1 EA032428B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072196P 2014-10-29 2014-10-29
PCT/US2015/056960 WO2016069376A1 (en) 2014-10-29 2015-10-22 Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1

Publications (2)

Publication Number Publication Date
EA201790766A1 true EA201790766A1 (ru) 2017-12-29
EA032428B1 EA032428B1 (ru) 2019-05-31

Family

ID=54478248

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790766A EA032428B1 (ru) 2014-10-29 2015-10-22 Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e-синтазы 1

Country Status (26)

Country Link
US (2) US9962375B2 (ru)
EP (1) EP3230278B1 (ru)
JP (1) JP6393830B2 (ru)
KR (1) KR101898829B1 (ru)
CN (1) CN107074829B (ru)
AR (1) AR102362A1 (ru)
AU (1) AU2015339644B2 (ru)
CA (1) CA2963321C (ru)
CL (1) CL2017001017A1 (ru)
CY (1) CY1122534T1 (ru)
DK (1) DK3230278T3 (ru)
EA (1) EA032428B1 (ru)
ES (1) ES2773439T3 (ru)
HR (1) HRP20200216T1 (ru)
HU (1) HUE047895T2 (ru)
JO (1) JO3581B1 (ru)
LT (1) LT3230278T (ru)
MX (1) MX2017005659A (ru)
NZ (1) NZ730724A (ru)
PL (1) PL3230278T3 (ru)
PT (1) PT3230278T (ru)
RS (1) RS59783B1 (ru)
SI (1) SI3230278T1 (ru)
TW (1) TWI605039B (ru)
WO (1) WO2016069376A1 (ru)
ZA (1) ZA201702198B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201627299A (zh) 2014-10-29 2016-08-01 美國禮來大藥廠 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物
EP3737370A4 (en) * 2018-01-09 2021-12-15 Brigham Young University COMPOSITIONS AND METHODS OF PAIN TREATMENT WITH WOGONIN
CN108558806B (zh) * 2018-05-31 2020-04-17 南京药石科技股份有限公司 一种5-氧代-四氢吡喃-3-羧酸酯的关键中间体及其制备方法
WO2020061475A2 (en) * 2018-09-21 2020-03-26 The Johns Hopkins University Compositions and methods for treating metabolic disorders
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
MX2022013619A (es) 2020-05-01 2022-11-16 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina que inhiben cd73.
TW202211917A (zh) * 2020-08-21 2022-04-01 南韓商治納輔醫藥科技有限公司 對前列腺素e2受體具有抑制活性的新穎化合物及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355010B1 (en) * 1999-03-31 2002-03-12 Coaxia, Inc. Intravascular spinal perfusion and cooling for use during aortic surgery
EP1627869B1 (en) * 2003-05-20 2012-05-02 Ajinomoto Co., Inc. Vanilloid receptor modulators
US20050239921A1 (en) * 2004-04-27 2005-10-27 Birmingham John N Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011023812A1 (en) * 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
JP5579862B2 (ja) * 2009-10-23 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミクロソームプロスタグランジンｅ２シンターゼ−１のインヒビター
WO2013146970A1 (ja) * 2012-03-29 2013-10-03 第一三共株式会社 新規キノリン誘導体
CA2916101A1 (en) * 2013-06-20 2014-12-24 Novasaid Ab Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors
TW201627299A (zh) 2014-10-29 2016-08-01 美國禮來大藥廠 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物

Also Published As

Publication number Publication date
CN107074829B (zh) 2020-11-13
ZA201702198B (en) 2018-12-19
US20170326128A1 (en) 2017-11-16
KR20170055025A (ko) 2017-05-18
EP3230278A1 (en) 2017-10-18
AU2015339644B2 (en) 2018-03-29
MX2017005659A (es) 2017-06-26
CA2963321C (en) 2020-01-14
PL3230278T3 (pl) 2020-06-01
EP3230278B1 (en) 2019-12-11
EA032428B1 (ru) 2019-05-31
US20180250282A1 (en) 2018-09-06
JP6393830B2 (ja) 2018-09-19
DK3230278T3 (da) 2020-01-20
CL2017001017A1 (es) 2017-12-11
TWI605039B (zh) 2017-11-11
CN107074829A (zh) 2017-08-18
JP2017537073A (ja) 2017-12-14
PT3230278T (pt) 2020-02-20
WO2016069376A1 (en) 2016-05-06
HUE047895T2 (hu) 2020-05-28
SI3230278T1 (sl) 2020-02-28
TW201627285A (zh) 2016-08-01
AU2015339644A1 (en) 2017-04-20
ES2773439T3 (es) 2020-07-13
AR102362A1 (es) 2017-02-22
CY1122534T1 (el) 2021-01-27
KR101898829B1 (ko) 2018-09-13
NZ730724A (en) 2018-09-28
BR112017007011A2 (pt) 2017-12-26
CA2963321A1 (en) 2016-05-06
LT3230278T (lt) 2020-03-10
JO3581B1 (ar) 2020-07-05
HRP20200216T1 (hr) 2020-05-15
US9962375B2 (en) 2018-05-08
RS59783B1 (sr) 2020-02-28

Similar Documents

Publication Publication Date Title
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MD20170016A2 (ru) Аминопиримидиновые соединения в качестве ингибиторов JAK
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
PH12017500095A1 (en) Imidazopyridazine compounds
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
TW201613864A (en) Novel compounds
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EA201692270A1 (ru) Производные нафтиридиндиона
MX2016010877A (es) Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG TJ TM